OncLive TV

Kedar Kirtane, MD, discusses the design of a phase 1b trial evaluating the TIL Tbio-4101 plus pembrolizumab in patients with advanced HNSCC.

Rohan Garje, MD, discusses the benefits of a multimodal approach for patients with small cell bladder cancer.

Cynthia Ma, MD, PhD, discusses unanswered questions regarding treatment sequencing for patients who develop CDK4/6 inhibitor–resistant breast cancer.

Arya Mariam Roy, MBBS discusses limitations of the Pathway trial evaluating the association between polygenic scores and survival outcomes in patients with breast cancer.

Karl Semaan, MD, MSc, discusses the utility of liquid biopsy epigenomic profiling for the detection of sarcomatoid renal cell carcinoma.

Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib in clear cell renal cell carcinoma.

Marc-Oliver Grimm, MD discusses the clinical implications, short comings, and future steps following a post-hoc analysis from the phase 3 ARASENS trial.

Chun Chao, PhD, MS, discusses the association between the use of broad-spectrum antibiotics and the risk of developing early-onset colorectal cancer.

Mikkael A. Sekeres, MD, discusses a subgroup analysis of treatment with imetelstat in patients with low-to intermediate-1–risk myelodysplastic syndrome.

Noa Biran, MD, discusses the implications of findings from the phase 3 DREAMM-7 trial in multiple myeloma.

Ranee Mehra, MD, discusses long-term follow-up data from the phase 2 E3311 trial in patients with HPV-associated oropharynx cancer.

Sumanta Kumar Pal, MD, FASCO, discusses preliminary findings from a phase 1 dose-escalation study of DFF332 in patients with advanced ccRCC.

Alfred L. Garfall, MD, MS discusses updated long-term data for teclistamab in patients with relapsed/refractory multiple myeloma.

David Braun, MD, PhD discusses the selection of immune checkpoint inhibitor use in clear cell renal cell carcinoma

Anthony M. Hunter, MD, discusses challenges associated with ruxolitinib-based toxicities in patients with myelofibrosis.

Amrita Krishnan, MD, discusses the characteristics and factors associated with a higher risk of early relapse for patients with multiple myeloma.

Jonathan C. Trent, MD, PhD discusses the current standard of care and existing unmet needs for patients with GIST.

Alexey Danilov, MD, PhD, discusses the evolution of treatment for patients with mantle cell lymphoma.

Tycel Phillips, MD, discusses the evolution of treatment strategies for patients with either chronic lymphocytic leukemia or mantle cell lymphoma.

Lori Wirth, MD, discusses questions about the treatment of patients with RET fusion+ thyroid cancer following the full approval of selpercatinib.

Moritz Fürstenau MD, discusses 4-year follow-up findings from the phase 3 GAIA/CLL13 trial in patients with CLL.

Aaron Gerds, MD, discusses disease progression patterns from the MOST trial in patients with low-risk myelofibrosis.

Tilak Sundaresan, MD, on results of a retrospective study of reasons why patients with pancreatic cancer decline treatment.

Andrew Davis, MD, discusses an ongoing phase 1 trial combining neratinib and trastuzumab deruxtecan in metastatic HER2-positive solid tumors.

Brian I. Rini, MD, FASCO, on findings from a biomarker analysis of the KEYNOTE-426 trial of pembrolizumab/axitinib vs sunitinib in renal cell carcinoma.

Mary Philip, MD, PhD, discusses research on the key transcriptional and epigenetic programs that regulate CD8 T cell fate decisions in cancer models.

Rom S. Leidner, MD, discusses the investigation of T-cell receptor–engineered T-cell immunotherapy for select patients with solid tumors.

Sarwish Rafiq, PhD, discusses how engineering metabolically fit, memory rich CAR T-cells may address barriers to CAR T-cell efficacy in solid tumors.

Noa Biran, MD, discusses avenues for future research and drug development in multiple myeloma.

Laurence Albigès, MD, PhD, discusses the potential predictive and prognostic value of circulating KIM-1 in patients with renal cell carcinoma.